A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors With Mutant KRAS
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2018
Price : $35 *
At a glance
- Drugs Cobimetinib (Primary) ; Duligotuzumab (Primary)
- Indications Anal cancer; Cervical cancer; Colorectal cancer; Lung cancer; Non-small cell lung cancer; Pancreatic cancer; Rectal cancer; Salivary gland cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Genentech
- 05 Jun 2018 Status changed to discontinued.
- 14 Jul 2016 Status changed from recruiting to completed.
- 02 Jun 2015 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov.